Sources
All 201 links and DOIs cited in the videos, drug pages, portal entries, survival data, the Support from the USA page and the News page, collected automatically at build time.
- doi:10.1001/jamaoncol.2024.4381
Used in: Drug: Lenvatinib (Lenvima); Level 2: FINAL_SCRIPTS_L2.md - doi:10.1002/bit.260110607
Used in: Drug: Doxorubicin - doi:10.1002/cncr.34163
Used in: Level 1: FINAL_SCRIPTS_v2.md - doi:10.1016/j.annonc.2021.08.1995
Used in: Drug: Mifamurtide (Mepact); Level 2: treatment_by_country.md - doi:10.1016/j.ejca.2018.11.027
Used in: Drug: Cisplatin; Drug: Doxorubicin; Drug: High-dose methotrexate; Level 1: FINAL_SCRIPTS_v2.md; Level 2: FINAL_SCRIPTS_L2.md - doi:10.1016/S1470-2045(14)71136-2
Used in: Drug: Sorafenib (Nexavar); Level 2: FINAL_SCRIPTS_L2.md - doi:10.1016/S1470-2045(16)30096-1
Used in: Drug: Zoledronic acid (Zometa); Level 2: treatment_by_country.md - doi:10.1016/S1470-2045(16)30214-5
Used in: Drug: Etoposide; Drug: Ifosfamide; Level 2: FINAL_SCRIPTS_L2.md - doi:10.1016/S1470-2045(17)30624-1
Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy; Level 2: FINAL_SCRIPTS_L2.md - doi:10.1016/S1470-2045(18)30742-3
Used in: Drug: Regorafenib (Stivarga); Level 2: FINAL_SCRIPTS_L2.md - doi:10.1016/S1470-2045(19)30825-3
Used in: Drug: Cabozantinib (Cabometyx); Level 2: FINAL_SCRIPTS_L2.md - doi:10.1038/205698a0
Used in: Drug: Cisplatin - doi:10.1056/NEJM198606193142502
Used in: Drug: High-dose methotrexate - doi:10.1093/annonc/mdr151
Used in: Drug: Sorafenib (Nexavar); Level 2: FINAL_SCRIPTS_L2.md - doi:10.1136/bmjopen-2018-025877
Used in: Level 2: treatment_by_country.md - doi:10.1136/jitc-2020-000798
Used in: Drug: Apatinib (rivoceranib) - doi:10.1158/1078-0432.CCR-24-2885
Used in: Drug: Denosumab (Xgeva) - doi:10.1158/1078-0432.CCR-25-3282
Used in: Level 2: treatment_by_country.md - doi:10.1186/s13569-016-0047-1
Used in: Level 2: treatment_by_country.md - doi:10.1200/JCO.18.02374
Used in: Drug: Regorafenib (Stivarga); Level 2: FINAL_SCRIPTS_L2.md - doi:10.1200/JCO.2008.14.0095
Used in: Drug: Mifamurtide (Mepact); Level 2: FINAL_SCRIPTS_L2.md - doi:10.1200/JCO.2014.58.0225
Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy; Level 2: FINAL_SCRIPTS_L2.md - doi:10.1634/theoncologist.2018-0542
Used in: Drug: Apatinib (rivoceranib); Level 2: FINAL_SCRIPTS_L2.md - http://static.cninfo.com.cn/finalpage/2020-11-03/1208675554.PDF
Used in: Drug: Cabozantinib (Cabometyx) - https://actaorthop.org/actao/article/view/29176
Used in: Survival data - https://amgen.com.cn/en/media/amgen-denosumab.html
Used in: Drug: Denosumab (Xgeva) - https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125320
Used in: Drug: Denosumab (Xgeva) - https://api.fda.gov/drug/drugsfda.json?search=application_number:BLA125514
Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA011719
Used in: Drug: High-dose methotrexate - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA018057
Used in: Drug: Cisplatin - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA018768
Used in: Drug: Etoposide - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA019763
Used in: Drug: Ifosfamide - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA021223
Used in: Drug: Zoledronic acid (Zometa) - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA021923
Used in: Drug: Sorafenib (Nexavar) - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA050467
Used in: Drug: Doxorubicin - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA203085
Used in: Drug: Regorafenib (Stivarga) - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA203756
Used in: Drug: Cabozantinib (Cabometyx) - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206947
Used in: Drug: Lenvatinib (Lenvima) - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA208692
Used in: Drug: Cabozantinib (Cabometyx) - https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA212937
Used in: Drug: Cisplatin - https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22CABOMETYX%22
Used in: Drug: Cabozantinib (Cabometyx) - https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22ETOPOPHOS%22
Used in: Drug: Etoposide - https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22NEXAVAR%22
Used in: Drug: Sorafenib (Nexavar) - https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22PEDMARK%22
Used in: Drug: Cisplatin - https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22Stivarga%22
Used in: Drug: Regorafenib (Stivarga) - https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22XGEVA%22
Used in: Drug: Denosumab (Xgeva) - https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22dexrazoxane%22
Used in: Drug: Doxorubicin - https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22glucarpidase%22
Used in: Drug: High-dose methotrexate - https://assets.hpra.ie/products/Human/15731/Licence_PA2299-028-001_11092023124600.pdf
Used in: Drug: Ifosfamide - https://assets.hpra.ie/products/Human/22078/Licence_PA0822-199-001_09112026181407.pdf
Used in: Drug: Cisplatin - https://assets.hpra.ie/products/Human/22092/Licence_PA0822-206-007_11092026121412.pdf
Used in: Drug: High-dose methotrexate - https://assets.hpra.ie/products/Human/27561/Licence_PA2315-083-001_20022024123027.pdf
Used in: Drug: Doxorubicin - https://assets.hpra.ie/products/Human/27660/Licence_PA2315-201-001_13032024133422.pdf
Used in: Drug: Etoposide - https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-10-357
Used in: Survival data - https://cjournal.hep.com.cn/0253-3626/CN/10.13406/j.cnki.cyxb.004023
Used in: Level 2: treatment_by_country.md - https://clinicaltrials.gov/study/NCT00470223
Used in: Portal: Zoledronic acid with chemotherapy (OS2006, NCT00470223) - https://clinicaltrials.gov/study/NCT02470091
Used in: Portal: Denosumab (COG AOST1321, NCT02470091) - https://clinicaltrials.gov/study/NCT03449108
Used in: Portal: LN-145 TIL therapy (NCT03449108) - https://clinicaltrials.gov/study/NCT03598595
Used in: Portal: Gemcitabine and docetaxel with hydroxychloroquine (NCT03598595) - https://clinicaltrials.gov/study/NCT03628209
Used in: Portal: Nivolumab with or without azacitidine (NCT03628209) - https://clinicaltrials.gov/study/NCT03643133
Used in: Portal: Mifamurtide added to post-operative chemotherapy in high-risk osteosarcoma (SARCOME13, NCT03643133) - https://clinicaltrials.gov/study/NCT03900793
Used in: Portal: Losartan with sunitinib (NCT03900793) - https://clinicaltrials.gov/study/NCT04417062
Used in: Portal: Olaparib with ceralasertib in recurrent osteosarcoma (NCT04417062) - https://clinicaltrials.gov/study/NCT04616560
Used in: Portal: Trastuzumab deruxtecan (DS-8201a) in recurrent osteosarcoma (NCT04616560) - https://clinicaltrials.gov/study/NCT04698785
Used in: Portal: Regorafenib maintenance (REGOMAIN, NCT04698785) - https://clinicaltrials.gov/study/NCT04758000
Used in: Portal: Metformin maintenance in high-risk bone sarcoma (NCT04758000) - https://clinicaltrials.gov/study/NCT04974008
Used in: Portal: OST31-164 maintenance after lung relapse - https://clinicaltrials.gov/study/NCT05019703
Used in: Portal: Atezolizumab with cabozantinib (TACOS) - https://clinicaltrials.gov/study/NCT05395741
Used in: Portal: Regorafenib (Regbone NCT05395741) - https://clinicaltrials.gov/study/NCT05492682
Used in: Portal: PeptiCRAd-1 with pembrolizumab (NCT05492682) - https://clinicaltrials.gov/study/NCT05590572
Used in: Portal: Sulfatinib with ifosfamide and etoposide (NCT05590572) - https://clinicaltrials.gov/study/NCT05660408
Used in: Portal: RNA lipid particle vaccine (RNA PRIME / NCT05660408) - https://clinicaltrials.gov/study/NCT05691478
Used in: Level 2: FINAL_SCRIPTS_L2.md - https://clinicaltrials.gov/study/NCT05726383
Used in: Portal: Mistletoe extract Iscador P (NCT05726383) - https://clinicaltrials.gov/study/NCT05830123
Used in: Portal: HS-20093 (B7-H3 antibody-drug conjugate) ARTEMIS-002 - https://clinicaltrials.gov/study/NCT06474676
Used in: Portal: attIL12-TIL (NCT06474676) - https://clinicaltrials.gov/study/NCT06714383
Used in: Portal: Trilaciclib with neoadjuvant chemotherapy (NCT06714383) - https://clinicaltrials.gov/study/NCT06892678
Used in: Portal: DFMO (eflornithine) maintenance - https://clinicaltrials.gov/study/NCT07142863
Used in: Portal: Envafolimab with neoadjuvant chemotherapy (NCT07142863) - https://clinicaltrials.gov/study/NCT07144254
Used in: Portal: Tegavivint with gemcitabine - https://clinicaltrials.gov/study/NCT07193550
Used in: Portal: Zanzalintinib (XL092) ZAMBONE - https://clinicaltrials.gov/study/NCT07357519
Used in: Portal: LNTH-2403 (LRRC15-targeted lutetium-177 antibody, Lu-TARGO, NCT07357519) - https://clinicaltrials.gov/study/NCT07428993
Used in: Portal: B7-H3 CAR T cells (SJCARB7H3-41BBL) after MAP chemotherapy - https://clinicaltrials.gov/study/NCT07477457
Used in: Portal: Gefitinib, trametinib, disulfiram and sunitinib with chemotherapy (OstEvo, NCT07477457) - https://clinicaltrials.gov/study/NCT07479732
Used in: Portal: Apatinib with liposomal irinotecan (NCT07479732) - https://clinicaltrials.gov/study/NCT07619950
Used in: Portal: Everolimus with lenvatinib (NCT07619950) - https://clinicaltrials.gov/study/NCT07725380
Used in: Portal: Domatinostat with sirolimus - https://clinicaltrials.gov/study/NCT07787429
Used in: Portal: Mifamurtide versus sorafenib (Dragonfly, NCT07787429) - https://clinicaltrials.gov/study/NCT07871864
Used in: Level 2: FINAL_SCRIPTS_L2.md; Portal: FOSTER platform trial (cabozantinib arm) - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e30eaef-5a09-4104-8a11-c32933eadeab
Used in: Drug: High-dose methotrexate - https://doi.org/10.1200/jco.18.02374
Used in: Portal: Regorafenib (SARC024 trial, osteosarcoma cohort) - https://drugs.dxy.cn/drug/0JhFqeRKboisKq8Gf6JQVA==
Used in: Drug: Apatinib (rivoceranib); Level 2: FINAL_SCRIPTS_L2.md - https://drugs.dxy.cn/pc/clinicalDecision/TJCplsplswFbnAoY9Pgxm4GGQHw==?ky=osa
Used in: Level 2: treatment_by_country.md - https://elevartx.com/2018/01/02/lskb-announces-official-nonproprietary-naming-of-apatinib-yn968d1-rivoceranib/
Used in: Drug: Apatinib (rivoceranib) - https://elevartx.com/2026/07/10/elevar-crl-july-2/
Used in: Drug: Apatinib (rivoceranib) - https://europepmc.org/article/med/31246277
Used in: Level 2: treatment_by_country.md - https://europepmc.org/article/PMC/PMC2528159
Used in: Survival data - https://europepmc.org/article/PMC/PMC5984426
Used in: Survival data - https://europepmc.org/article/PMC/PMC7469730
Used in: Survival data - https://healx.ai/healx-announces-first-patient-dosed-in-phase-1-2-trial-to-evaluate-the-effect-of-hlx-4310-on-metastatic-recurrence-and-progression-in-sarcomas-with-a-focus-on-osteosarcoma/
Used in: News: First patient dosed in Healx trial of HLX-4310, with a focus on osteosarcoma - https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-partner-takeda-receives-approval-japan
Used in: Drug: Cabozantinib (Cabometyx) - https://ir.ostherapies.com/news-events/press-releases/detail/128/os-therapies-achieves-incremental-alignment-with-fda-and
Used in: News: OS Therapies reports further FDA alignment and a UK Project Orbis invitation for OST-HER2 - https://ir.ostherapies.com/news-events/press-releases/detail/56/os-therapies-completes-acquisition-of-advaxis
Used in: News: OS Therapies completes purchase of Ayala's listeria immunotherapy assets - https://ir.ostherapies.com/news-events/press-releases/detail/64/os-therapies-partners-with-eversana-for-the-u-s
Used in: News: OS Therapies partners with EVERSANA to prepare a US launch of OST-HER2 - https://netsarc.sarcomabcb.org/
Used in: Level 2: treatment_by_country.md - https://njguloulib.yuntsg.com/ueditor/jsp/upload/file/20210608/1623115700638048095.pdf
Used in: Level 2: treatment_by_country.md - https://osinst.org/
Used in: Support from the USA - https://osinst.org/blog/2025-grant-recipients/
Used in: News: Osteosarcoma Institute awards more than $1.5 million for four research projects - https://osinst.org/blog/andreas-story/
Used in: News: Andrea Helfer on life more than 30 years after childhood osteosarcoma - https://osinst.org/blog/anthony-olivero-story/
Used in: News: Anthony Olivero is cancer-free two years after a five-year outlook as a teenager - https://osinst.org/donate/
Used in: Support from the USA - https://osinst.org/partnering-for-progress/
Used in: Support from the USA - https://osinst.org/researchers/
Used in: Support from the USA - https://pdf.marketpublishers.com/shcri/investigation-report-on-chinese-sorafenib-market-2018-2022.pdf
Used in: Drug: Sorafenib (Nexavar) - https://pharm.ncmi.cn/zysjk/ypjkyp/202312/t20231205_399737.html
Used in: Drug: Zoledronic acid (Zometa) - https://pmc.ncbi.nlm.nih.gov/articles/PMC11343645/
Used in: Drug: Doxorubicin; Level 2: FINAL_SCRIPTS_L2.md - https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/
Used in: Drug: Cisplatin; Drug: Doxorubicin; Drug: Etoposide; Drug: High-dose methotrexate; Drug: Ifosfamide; Drug: Lenvatinib (Lenvima); Drug: Regorafenib (Stivarga); Level 2: FINAL_SCRIPTS_L2.md; Level 2: treatment_by_country.md - https://pmc.ncbi.nlm.nih.gov/articles/PMC2813207/
Used in: Survival data - https://pmc.ncbi.nlm.nih.gov/articles/PMC4414626/
Used in: Survival data - https://pmc.ncbi.nlm.nih.gov/articles/PMC5834019/
Used in: Level 2: treatment_by_country.md - https://pmc.ncbi.nlm.nih.gov/articles/PMC6162271/
Used in: Level 2: FINAL_SCRIPTS_L2.md - https://pmc.ncbi.nlm.nih.gov/articles/PMC6506906/
Used in: Survival data - https://pubmed.ncbi.nlm.nih.gov/11821461/
Used in: Survival data - https://pubmed.ncbi.nlm.nih.gov/21527590/
Used in: Portal: Sorafenib (Italian Sarcoma Group phase 2) - https://pubmed.ncbi.nlm.nih.gov/21913189/
Used in: Survival data - https://pubmed.ncbi.nlm.nih.gov/25498219/
Used in: Portal: Sorafenib with everolimus (Italian Sarcoma Group, NCT01804374) - https://pubmed.ncbi.nlm.nih.gov/26033801/
Used in: Portal: Pegylated interferon alfa-2b maintenance (EURAMOS-1 good responders) - https://pubmed.ncbi.nlm.nih.gov/27569442/
Used in: Portal: Cisplatin (MAP chemotherapy); Portal: Doxorubicin (MAP chemotherapy); Portal: High-dose methotrexate (MAP chemotherapy); Portal: Ifosfamide with etoposide (EURAMOS-1 MAPIE) - https://pubmed.ncbi.nlm.nih.gov/28833209/
Used in: Survival data - https://pubmed.ncbi.nlm.nih.gov/28988646/
Used in: Portal: Pembrolizumab (SARC028) - https://pubmed.ncbi.nlm.nih.gov/30477937/
Used in: Portal: Regorafenib (REGOBONE trial, NCT02389244) - https://pubmed.ncbi.nlm.nih.gov/31081028/
Used in: Level 2: treatment_by_country.md - https://pubmed.ncbi.nlm.nih.gov/31586757/
Used in: Portal: Glembatumumab vedotin (NCT02487979) - https://pubmed.ncbi.nlm.nih.gov/32078813/
Used in: Portal: Cabozantinib (CABONE trial) - https://pubmed.ncbi.nlm.nih.gov/35192571/
Used in: Survival data - https://pubmed.ncbi.nlm.nih.gov/3520317/
Used in: Survival data - https://pubmed.ncbi.nlm.nih.gov/39418029/
Used in: Portal: Lenvatinib with ifosfamide and etoposide (ITCC-050 and OLIE) - https://pubmed.ncbi.nlm.nih.gov/40455577/
Used in: Survival data - https://pubmed.ncbi.nlm.nih.gov/5225072/
Used in: Survival data - https://sarcoma.org.uk/research/reactivating-the-immune-system-to-tackle-osteosarcoma-that-has-spread-to-the-lungs/
Used in: Portal: Tin mesoporphyrin (SnMP) for lung metastases (Sarcoma UK funded) - https://sotio.com/news-publications/news/sotio-receives-u-s-fda-orphan-drug-designation-for-sot106-a-potential-best-in-class-adc-for-sarcoma
Used in: News: US FDA grants orphan drug designation to SOT106 for osteosarcoma - https://web.archive.org/web/20190423133424/https:/www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm
Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy - https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=143401
Used in: Drug: Mifamurtide (Mepact); Level 2: FINAL_SCRIPTS_L2.md; Level 2: treatment_by_country.md - https://www.bayer.com/media/en-us/bayer-receives-approval-in-china-for-stivargar-regorafenib-for-the-second-line-systemic-treatment-of-liver-cancer/
Used in: Drug: Regorafenib (Stivarga) - https://www.bbc.com/news/articles/cjrng9nxjd3o
Used in: News: Family of Glasgow DJ Niamh Jobson launch an osteosarcoma research fund - https://www.bcrt.org.uk/news/2025/december/introducing-our-first-ever-youth-ambassador
Used in: News: Annabel Kiki becomes the Bone Cancer Research Trust's first Youth Ambassador - https://www.bcrt.org.uk/news/2026/01/exploring-new-ways-to-help-the-immune-system-fight-osteosarcoma
Used in: News: Bone Cancer Research Trust funds work to help the immune system fight osteosarcoma - https://www.bcrt.org.uk/research/completed-research-projects/iconic
Used in: Portal: ICONIC: Improving Outcomes through Collaboration in Osteosarcoma (registry and observational study) - https://www.bcrt.org.uk/research/current-research-projects/advancing-iconic-(%E2%80%98ad-iconic%E2%80%99)
Used in: Portal: Ad-ICONIC: Advancing the ICONIC trial - https://www.bcrt.org.uk/research/current-research-projects/kinder-drugs-to-treat-osteosarcoma
Used in: Portal: Kinder drugs: tumour-targeted methotrexate prodrugs - https://www.bcrt.org.uk/research/current-research-projects/mimicking-the-journey-through-the-bloodstream-exploring-how-osteosarcoma-cells-spread-and-survive-elsewhere-in-the-body
Used in: Portal: Mimicking the journey through the bloodstream: circulating osteosarcoma cells - https://www.bcrt.org.uk/research/current-research-projects/searching-for-new-drugs-to-treat-osteosarcoma
Used in: Portal: Searching for new drugs to treat osteosarcoma (preclinical validation of novel compounds) - https://www.bcrt.org.uk/research/current-research-projects/stopping-the-alpha-a-potential-new-treatment-approach-for-osteosarcoma
Used in: Portal: Stopping the alpha: IKKα inhibitors for osteosarcoma - https://www.bcrt.org.uk/research/current-research-projects/towards-precision-medicine-in-osteosarcoma
Used in: Portal: PARP inhibitors for RB1-mutated osteosarcoma (Bone Cancer Research Trust funded) - https://www.bjcancer.org.cn/Html/News/Articles/8768.html
Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy - https://www.cancer.gov/about-cancer/treatment/drugs/methotrexate-sodium
Used in: Drug: High-dose methotrexate; Level 2: FINAL_SCRIPTS_L2.md - https://www.cancer.gov/types/bone/hp/osteosarcoma-treatment-pdq
Used in: Level 2: FINAL_SCRIPTS_L2.md; Level 2: treatment_by_country.md - https://www.cancer.org/cancer/types/osteosarcoma/detection-diagnosis-staging/survival-rates.html
Used in: Survival data - https://www.cancerresearchuk.org/about-cancer/bone-cancer/survival
Used in: Survival data - https://www.cancerresearchuk.org/about-cancer/bone-cancer/treatment/chemotherapy
Used in: Level 2: FINAL_SCRIPTS_L2.md - https://www.cancertherapyadvisor.com/ddi/bone-cancer-treatment-pharmacologic-management/
Used in: Drug: Cabozantinib (Cabometyx); Drug: Ifosfamide; Drug: Regorafenib (Stivarga); Drug: Sorafenib (Nexavar); Level 2: treatment_by_country.md - https://www.eisai.com/news/2018/news201818.html
Used in: Drug: Lenvatinib (Lenvima) - https://www.eisai.com/news/2018/news201877.html
Used in: Drug: Lenvatinib (Lenvima) - https://www.ema.europa.eu/en/documents/product-information/mepact-epar-product-information_en.pdf
Used in: Level 2: treatment_by_country.md - https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx
Used in: Drug: Cabozantinib (Cabometyx); Drug: Denosumab (Xgeva); Drug: Lenvatinib (Lenvima); Drug: Mifamurtide (Mepact); Drug: Pembrolizumab (Keytruda) and immunotherapy; Drug: Regorafenib (Stivarga); Drug: Sorafenib (Nexavar); Drug: Zoledronic acid (Zometa) - https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima
Used in: Drug: Lenvatinib (Lenvima) - https://www.ema.europa.eu/en/medicines/human/EPAR/mepact
Used in: Drug: Mifamurtide (Mepact); Portal: Mifamurtide (Mepact) - https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3189
Used in: News: EMA grants orphan designations to sirolimus and domatinostat for osteosarcoma - https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3190
Used in: News: EMA grants orphan designations to sirolimus and domatinostat for osteosarcoma - https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors
Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy - https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-and-berahyaluronidase-alfa-pmph-subcutaneous-injection
Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy - https://www.hengrui.com/en/media/detail-423.html
Used in: Drug: Apatinib (rivoceranib) - https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/memos-a-eurosarc-study-of-mifamurtide-in-advanced-osteosarcoma/
Used in: Portal: Mifamurtide in advanced osteosarcoma (MEMOS, ISRCTN82138287) - https://www.iarc.who.int/reference/bone-tumours-in-european-children-and-adolescents-1978-1997-report-from-the-automated-childhood-cancer-information-system-project/
Used in: Survival data - https://www.indianmed.cn/drug-news/t2nz0hzctd4y.html
Used in: Drug: Cabozantinib (Cabometyx) - https://www.linchuangsy.com/Newsqa/Show/14269.html
Used in: Drug: Cabozantinib (Cabometyx) - https://www.medicines.org.uk/emc/product/10514/smpc
Used in: Drug: Etoposide - https://www.medicines.org.uk/emc/product/1834/smpc
Used in: Drug: Ifosfamide - https://www.medicines.org.uk/emc/product/210/smpc
Used in: Drug: Zoledronic acid (Zometa) - https://www.medicines.org.uk/emc/product/2498/smpc
Used in: Drug: Pembrolizumab (Keytruda) and immunotherapy - https://www.medicines.org.uk/emc/product/3788/smpc
Used in: Drug: Cisplatin - https://www.medicines.org.uk/emc/product/7205/smpc
Used in: Drug: Zoledronic acid (Zometa) - https://www.medicines.org.uk/emc/product/8443/smpc
Used in: Drug: Doxorubicin - https://www.medicines.org.uk/emc/product/8504/smpc
Used in: Drug: High-dose methotrexate - https://www.nature.com/articles/s41416-024-02868-4
Used in: Level 2: treatment_by_country.md - https://www.nice.org.uk/guidance/ta235/chapter/1-Guidance
Used in: Level 2: FINAL_SCRIPTS_L2.md - https://www.nice.org.uk/guidance/ta235/chapter/1-Recommendations
Used in: Level 2: treatment_by_country.md - https://www.pnas.org/doi/10.1073/pnas.1419260111
Used in: Level 2: FINAL_SCRIPTS_L2.md - https://www.roswellpark.org/newsroom/202605-fl118-granted-fda-rare-pediatric-disease-designation-orphan-drug-designation
Used in: News: FDA grants rare paediatric and orphan designations to FL118 for osteosarcoma - https://www.sec.gov/Archives/edgar/data/822206/000110465909040297/a09-16803_2ex99d2.htm
Used in: Drug: Mifamurtide (Mepact) - https://www.sohu.com/a/1076774583_122732456
Used in: Drug: Cabozantinib (Cabometyx) - https://www.targetedonc.com/view/rivoceranib-plus-camrelizumab-resubmitted-to-fda-in-frontline-hcc
Used in: Drug: Apatinib (rivoceranib) - https://www.unc.edu/posts/2026/02/04/after-cancer-battle-camden-bailey-leaves-lasting-carolina-legacy/
Used in: News: UNC-Chapel Hill remembers Camden Bailey, who founded a fund for osteosarcoma research - https://www.yaodey.com/drug/state_60.html
Used in: Drug: Cabozantinib (Cabometyx) - https://www.yaodey.com/news/28242.html
Used in: Level 2: FINAL_SCRIPTS_L2.md - https://www.yaopinnet.com/H/H13/H20040813.htm
Used in: Drug: Cisplatin - https://www.yaopinnet.com/h/h18/H20041318.htm
Used in: Drug: Doxorubicin - https://www.yaopinnet.com/H/H45/H20263245.htm
Used in: Drug: Etoposide - https://www.yaopinnet.com/h/h57/H20183157.htm
Used in: Drug: Zoledronic acid (Zometa) - https://www.yaopinnet.com/h/h92/H20054692.htm
Used in: Drug: High-dose methotrexate - https://www.yaozs.com/z24590/
Used in: Drug: Ifosfamide